Color-dependent Melatonin Suppression

Melatonin Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02936674
• Other study ID #: IRB-10165
• Status: Completed
• Phase: N/A
• First received: October 7, 2016
• Last updated: January 3, 2018
• Start date: October 2016
• Est. completion date: June 2017

Study information

• Verified date: January 2018
• Source: VA Palo Alto Health Care System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the effects of complex, broad-band spectra light on the production of melatonin in humans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Stable health

• Normal color vision

• Normal hearing

• 18-35 years old

Exclusion Criteria:

• Significant depressive symptoms

• Pregnant or nursing

• Ocular pathologies

• Unstable or severe medical or psychiatric condition

• Extreme morning/evening type

• Regular smoker

• Use of medications that impact ocular function

• Alcohol use disorder

• Use of illegal drugs

• Irregular use of antihistamines, antidepressants, or sleeping medications

Related Conditions & MeSH terms

• Melatonin

Intervention

Device:
• Light - standard
Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
• Light - alternate
Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)

Locations

Country	Name	City	State
United States	VA Palo Alto Health Care System	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
VA Palo Alto Health Care System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Melatonin suppression	The amount of declination of salivary melatonin concentrations between the start of the light and the end of the light (4 hours later) will be compared between the conditions.	4 Hours